Navigation Links
Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
Date:1/31/2013

OSLO, January 31, 2013 /PRNewswire/ --

18-24 patients will be included in the clinical Phase I/II study. Results from the Phase I part are expected in first half of 2013.

Principal investigator and oncologist Svein Dueland states: "It is exciting that we now recruit patients for this study, which originates from collaboration between Oslo University Hospital and Norsk Hydro. Participation in clinical trials is an important part of the treatment we can offer cancer patients."

Hanne Mette D Kristensen, CEO, says: "We are proud that Targovax now has its first drug in clinical Phase I/II, only two years after the company's inception. The study will run at the Radium Hospital at Oslo University Hospital, international pioneers in development of immunotherapy and cancer vaccines. TG01 has already shown promising results in patients. If these results are confirmed by systematic studies, TG01 may mean the first real change for pancreatic cancer patients."

Targovax is owned by The Radium Hospital Research Foundation, Birk Venture and RO Invest, inventors and management. The company has received grant from Innovation Norway for running the clinical Phase I/II trial in collaboration with OUS, The Radium Hospital.

Targovax

Targovax is a cancer biotech-company started in October 2010. The TG01 cancer vaccine is therapeutic; it is given as treatment to patients who already have cancer to prevent recurrence, and educates the body's immune system to recognize and kill cancer cells.

Approximately 80-90% of pancreatic cancers have RAS mutations. Cancers with RAS mutations have proved to be difficult to treat with current treatment, and there is a significant unmet medical need.

A follow-up review of clinical trials from the end of the 90'es indicates increased survival for patients treated with TG01. Some of these patients are still alive more than ten years later.
'/>"/>

SOURCE Targovax AS
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced ... for the compounding, packaging and distributing of its naltrexone tablets. ... the United States . KRS Global ... naltrexone tablets in various strengths for individual patients in response ...
(Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, ... Concepts (AMC), the largest multi-specialty Orthopedic, Spine and Neuro ... The award gives Bacterin ,pre-approved, ready-access to ...
... PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 ... announced a collaboration for the process development and cGMP ... used in Phase I and Phase II clinical trials. ... is prostatectomy, or removal of the prostate," noted David ...
Cached Medicine Technology:Bacterin Awarded Approved Vendor Status for American Medical Concepts' Network of Hospitals in the Northwest U.S. 2Goodwin Biotechnology Announces a Collaboration with Spectros Corporation 2
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance ... reducing the costs of an auto insurance policy . , ... lower prices for their vehicle insurance policies. The safety a vehicle ... costs. Because of this, drivers should always carry a first ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Bristol-Myers Squibb Company,(NYSE: BMY ) will announce results ... During a conference call on October 25 at 10:30 ... will,address inquiries from investors and analysts. Investors and ... live,webcast of the call at http://www.bms.com/ir or ...
... increase the risk of bleeding from the stomach, according ... , The antidepressant drugs, selective serotonin reuptake inhibitors known ... Clinical Excellence (NICE). SSRIs are very widely used in ... last year, probably to about 1.5 million patients. , ...
... to Launch Medi-Scripts PLUS - Prescription Pads with ... ... Medi-Promotions, Inc.,the originator of Medi-Scripts(R) prescription pads, today announced that,it ... company,s next generation prescription pad model. Being launched this,month at ...
... Health Management Systems,Inc. (HMS) today announced that ... Inc. d/b/a/ Permedion, an independent health care quality ... this,acquisition, HMS augments its portfolio of program integrity ... agencies and,managed care organizations. Permedion utilizes advanced ...
... 8 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") ... company that develops, manufactures and markets advanced in-,vitro ... systems, today announced that it has posted its ... http://ir.chinameditech.com . The 2006,annual report includes ...
... treatment for breast cancer differs between African-American women and ... insurance type. The study appears in the November 15, ... American Cancer Society. , Dr. Mousumi Banerjee of ... from Wayne State University and Dr. William Hryniuk from ...
Cached Medicine News:Health News:Antidepressants and painkillers - a dangerous combination 2Health News:Medi-Promotions Hires Industry Executive to Expand its Medi-Scripts Prescription Pad Model 2Health News:HMS Acquires Permedion to Expand Clinical Review Capabilities 2Health News:China Medical Technologies to Post 2006 Annual Report on Its Website 2Health News:Differences observed between black and white women in use of breast cancer therapy 2
... Cytometry Concentrate is for use as a ... cytometry. Each 70ml bottle of Cytometry Concentrate ... distilled water. Compared to Cubitainers, Streck Cytometry ... and saves money without compromising performance. Streck ...
... CD34 is a stabilized preparation ... can be used as a ... CD34 positive cells. It is ... ProCOUNT gating strategies. CD-Chex CD34 ...
... A lytic reagent manufactured ... determination of hemoglobin and ... Agent IIIA is manufactured ... the Abbott CELL-DYN® 1700. ...
Streck-Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3000. The shelf life is two years from the date of manufacture....
Medicine Products: